Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANIDIAP
2025-522742-46-00Phase 4Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of canagliflozin in chronic kidney disease (CKD) and end-stage kidney disease (ESKD), sponsored by University Medical Center Groningen. Primary endpoint: Overall percentage of receptor occupancy. Planned start Feb 2026; status: authorised.
02
Drugs
canagliflozin
03
Conditions
chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2025-522742-46-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522742-46-00.